JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 6, 2003; DOI: 10.1124/jpet.102.047134


0022-3565/03/3053-956-965$20.00
JPET 305:956-965, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.047134v1
305/3/956    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ansah, T.-A.
Right arrow Articles by Blakely, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ansah, T.-A.
Right arrow Articles by Blakely, R. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL

NEUROPHARMACOLOGY

Calcium-Dependent Inhibition of Synaptosomal Serotonin Transport by the {alpha}2-Adrenoceptor Agonist 5-Bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304)

Twum-Ampofo Ansah, Sammanda Ramamoorthy, Sylvia Montañez, Lynette C. Daws, and Randy D. Blakely

Department of Pharmacology, Meharry Medical College, Nashville, Tennessee (T.A.A); Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina (S.R.); Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas (S.M., L.C.D.); and Department of Pharmacology and Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.B.)

Termination of serotonergic transmission is the function of the plasma membrane 5-hydroxytryptamine (serotonin, 5-HT) transporter (SERT), which is also a high-affinity target in vivo for antidepressants, amphetamines, and cocaine. Studies show that SERT is regulated by protein kinase- and phosphataselinked pathways. In contrast, receptor-linked modulation of SERT is only minimally defined. Because noradrenergic stimulation is reported to influence 5-HT release, we explored possible presynaptic adrenoceptor-mediated regulation of SERT. In mouse forebrain synaptosomes, {alpha}2-adrenoceptor agonists, particularly 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304), triggered a concentration- and time-dependent decrease in 5-HT transport. In contrast, 5-HT uptake was unaffected by pharmacological {alpha}1-adrenoceptor activation. Kinetically, UK14304 significantly decreased the apparent substrate affinity, Km without altering transport capacity, Vmax. At concentrations of UK14304 supporting maximal inhibition of SERT in synaptosomes, no effect on SERT in transfected cells was observed, suggesting that UK14304 acts indirectly to reduce SERT activity. The effect of UK14304 on 5-HT uptake was not shared by other Na+ and Cl-dependent transporters. UK14304-mediated inhibition of SERT function was yohimbine-sensitive, as was inhibition triggered by norepinephrine, and was abolished in the absence of added Ca2+. Moreover, UK14304 effects were attenuated by voltage-sensitive Ca2+ channel antagonists, consistent with a role for Ca2+ in UK14304 effects. In agreement with altered 5-HT transport activity in vitro, in vivo chronoamperometry studies revealed that UK14304 significantly prolonged 5-HT clearance. Our findings suggest that UK14304 modulates SERT function in vitro and in vivo via signaling pathways, possibly supported by an influx of Ca2+ through voltage-sensitive Ca2+ channels.


Received November 21, 2002; accepted February 21, 2003.

Address correspondence to: Dr. Twum A. Ansah, Department of Pharmacology, Meharry Medical College, 1005 D.B. Todd Blvd., Nashville, TN 37208. E-mail: tansah{at}mmc.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C.-B. Zhu, J. A. Steiner, J. L. Munn, L. C. Daws, W. A. Hewlett, and R. D. Blakely
Rapid Stimulation of Presynaptic Serotonin Transport by A3 Adenosine Receptors
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 332 - 340.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Chen, M. R. Tilley, H. Wei, F. Zhou, F.-M. Zhou, S. Ching, N. Quan, R. L. Stephens, E. R. Hill, T. Nottoli, et al.
Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter
PNAS, June 13, 2006; 103(24): 9333 - 9338.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-B. Zhu, A. M. Carneiro, W. R. Dostmann, W. A. Hewlett, and R. D. Blakely
p38 MAPK Activation Elevates Serotonin Transport Activity via a Trafficking-independent, Protein Phosphatase 2A-dependent Process
J. Biol. Chem., April 22, 2005; 280(16): 15649 - 15658.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. J. Samuvel, L. D. Jayanthi, N. R. Bhat, and S. Ramamoorthy
A Role for p38 Mitogen-Activated Protein Kinase in the Regulation of the Serotonin Transporter: Evidence for Distinct Cellular Mechanisms Involved in Transporter Surface Expression
J. Neurosci., January 5, 2005; 25(1): 29 - 41.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C.-B. Zhu, W. A. Hewlett, I. Feoktistov, I. Biaggioni, and R. D. Blakely
Adenosine Receptor, Protein Kinase G, and p38 Mitogen-Activated Protein Kinase-Dependent Up-Regulation of Serotonin Transporters Involves Both Transporter Trafficking and Activation
Mol. Pharmacol., June 1, 2004; 65(6): 1462 - 1474.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.